High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine |
| |
| Affiliation: | 1. SAFOSO, Waldeggstrasse 1, Bern Liebefeld, CH 3097, Switzerland;2. Department of Epidemiological Sciences, Animal and Plant Health Agency, Woodham Lane, New Haw, Surrey, KT15 3NB, United Kingdom;3. Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d''Aosta (IZSPLVA), Italy;1. Department of Nephrology, Hospital del Mar, Autonomous University of Barcelona, Spain;2. Institut Mar d''Investigacions Mediques, Barcelona, Spain;3. REDINREN, Instituto Carlos III, Madrid, Spain;4. Department of Internal Medicine, Hospital del Mar, Autonomous University of Barcelona, Spain;5. Oxford NIHR Musculoskeletal Biomedical Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford OX3 7HE, United Kingdom of Great Britain and Northern Ireland;6. CIBERFES, Instituto Carlos III, Madrid, Spain;1. Department of Medical Microbiology, Capital Medical University, Beijing, China;2. Center for Disease Prevention and Control, Chaoyang District, Beijing, China;3. Beijing You''an Hospital, Capital Medical University, Beijing, China;4. Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland |
| |
| Abstract: | There is increasing interest in prevention of pertussis in adults by vaccination, but little is known about the duration of the antibody response to pertussis, diphtheria or tetanus in reduced antigen content vaccines formulated for adult use. Follow-up of a clinical trial including 550 adults comparing responses to reduced antigen content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, or a licensed Td vaccine, provided the opportunity to evaluate this. Blood samples were collected at 0, 1, 12, 24 and 36 months following vaccination; of the original cohort of 550, 387 subjects (dTpa group N = 310, Td + pa group N = 77) were tested at month 36. Following a decrease in antibody levels against all vaccine antigens between one and 24 months following vaccination, levels stabilized during the third year, remaining higher at 36 months than pre-vaccination for all vaccine antigens. In particular, more than 90% of subjects remained seropositive for pertussis toxin and pertactin antibodies at 36 months after vaccination, suggesting ongoing protection against pertussis. Adult-formulated dTpa vaccines could replace Td for routine booster vaccination of older individuals. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
